A groundbreaking study funded by Cancer Research UK and led by Queen Mary University of London reveals that approximately 200 lives have been saved in England due to the human papillomavirus (HPV) vaccine, with more lives expected to be protected as vaccinated individuals age. The study, published in The Lancet, highlights the vaccine’s powerful role in preventing cervical cancer and moving toward its eradication nationwide.
Children vaccinated at ages 12 to 13 face an almost zero risk of dying from cervical cancer before turning 30. Notably, from 2020 to 2024, there were no deaths recorded from cervical cancer among women aged 20 to 24 in England for the first time, marking a significant milestone. Between 2015 and 2019, deaths in this age group dropped by 80%, underscoring the vaccine’s effectiveness.
The HPV vaccine, introduced for girls in 2008 and extended to boys in 2019, targets several high-risk HPV types responsible for 99.7% of cervical cancers. Beyond cervical cancer, the vaccine also offers protection against genital warts and certain head and neck cancers, such as those affecting the mouth and throat.
Despite this remarkable progress, vaccination rates remain a concern. In the 2024–2025 school year, 71.7% of girls and 67% of boys in Year 8 received the vaccine in England, with slightly higher uptake in Years 9 and 10. However, these rates fall short of the World Health Organization’s 90% target, especially in London, where coverage dips to 62.6% for girls and 57.7% for boys.
Cancer Research UK warns that declining vaccination rates endanger these advances. Michelle Mitchell, CEO of Cancer Research UK, emphasizes the urgent need for targeted efforts to reach underserved communities and stresses the importance of both vaccination and cervical screening in the fight against cervical cancer.
Lead author Professor Peter Sasieni states that the current achievements represent just the beginning, with many more lives expected to be saved as vaccinated cohorts grow older. NHS Vaccination Director Caroline Temmink echoes this optimism, emphasizing the vaccine’s safety and the NHS’s commitment to eliminating cervical cancer by 2040.
The HPV vaccine is a crucial public health tool, not only preventing cervical cancer but promising a future where such cancers are exceedingly rare. Parents, guardians, and eligible individuals are urged to ensure vaccination uptake to protect the next generation.